Compositions and methods for treating liver disease
Compositions and methods for treating liver disease in a subject by increasing the transport or retention of transcription factor HNF4 [alpha] into the nucleus of liver cells in the subject are disclosed. In some embodiments, the methods comprise upregulating the expression or function of one or mor...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | OSTROWSKA ANNA TAFARON, ERIC, N FRAUENHOF NAVARRO NATALIA FOX IAN MICHALOPOULOS, GEORGE, K TAKEISHI KAZUKI BELL ANDREW GUZMAN LEPE JAVIER SOTO GUTIERREZ ALBERTO HEINER SOPHIE |
| description | Compositions and methods for treating liver disease in a subject by increasing the transport or retention of transcription factor HNF4 [alpha] into the nucleus of liver cells in the subject are disclosed. In some embodiments, the methods comprise upregulating the expression or function of one or more transcription factors selected from the group consisting of PROX1, NR5A2, NR0B2, MTF1, SREBP1, EP300 and POM121C and functional fragments thereof, and/or down-regulating the expression or function of one or more transcription factors selected from the group consisting of DNAJB1/HSP40, ATF6, ATF4 and PERK and functional fragments thereof.
公开了通过增加转录因子HNF4α到受试者的肝细胞的核中的转运或保留来治疗受试者肝病的组合物和方法。在一些实施方式中，所述方法包括上调一种或多种选自由PROX1、NR5A2、NR0B2、MTF1、SREBP1、EP300和POM121C组成的组的转录因子及其功能性片段的表达或功能，和/或下调一种或多种选自DNAJB1/HSP40、ATF6、ATF4和PERK的转录因子及其功能性片段的表达或功能。 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN115209923A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN115209923A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN115209923A3</originalsourceid><addsrcrecordid>eNrjZDB2zs8tyC_OLMnMzytWSMxLUchNLcnITylWSMsvUigpSk0sycxLV8jJLEstUkjJLE5NLE7lYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxzn6GhqZGBpaWRsaOxsSoAQAelCyt</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Compositions and methods for treating liver disease</title><source>esp@cenet</source><creator>OSTROWSKA ANNA ; TAFARON, ERIC, N ; FRAUENHOF NAVARRO NATALIA ; FOX IAN ; MICHALOPOULOS, GEORGE, K ; TAKEISHI KAZUKI ; BELL ANDREW ; GUZMAN LEPE JAVIER ; SOTO GUTIERREZ ALBERTO ; HEINER SOPHIE</creator><creatorcontrib>OSTROWSKA ANNA ; TAFARON, ERIC, N ; FRAUENHOF NAVARRO NATALIA ; FOX IAN ; MICHALOPOULOS, GEORGE, K ; TAKEISHI KAZUKI ; BELL ANDREW ; GUZMAN LEPE JAVIER ; SOTO GUTIERREZ ALBERTO ; HEINER SOPHIE</creatorcontrib><description>Compositions and methods for treating liver disease in a subject by increasing the transport or retention of transcription factor HNF4 [alpha] into the nucleus of liver cells in the subject are disclosed. In some embodiments, the methods comprise upregulating the expression or function of one or more transcription factors selected from the group consisting of PROX1, NR5A2, NR0B2, MTF1, SREBP1, EP300 and POM121C and functional fragments thereof, and/or down-regulating the expression or function of one or more transcription factors selected from the group consisting of DNAJB1/HSP40, ATF6, ATF4 and PERK and functional fragments thereof.
公开了通过增加转录因子HNF4α到受试者的肝细胞的核中的转运或保留来治疗受试者肝病的组合物和方法。在一些实施方式中，所述方法包括上调一种或多种选自由PROX1、NR5A2、NR0B2、MTF1、SREBP1、EP300和POM121C组成的组的转录因子及其功能性片段的表达或功能，和/或下调一种或多种选自DNAJB1/HSP40、ATF6、ATF4和PERK的转录因子及其功能性片段的表达或功能。</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221018&DB=EPODOC&CC=CN&NR=115209923A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221018&DB=EPODOC&CC=CN&NR=115209923A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>OSTROWSKA ANNA</creatorcontrib><creatorcontrib>TAFARON, ERIC, N</creatorcontrib><creatorcontrib>FRAUENHOF NAVARRO NATALIA</creatorcontrib><creatorcontrib>FOX IAN</creatorcontrib><creatorcontrib>MICHALOPOULOS, GEORGE, K</creatorcontrib><creatorcontrib>TAKEISHI KAZUKI</creatorcontrib><creatorcontrib>BELL ANDREW</creatorcontrib><creatorcontrib>GUZMAN LEPE JAVIER</creatorcontrib><creatorcontrib>SOTO GUTIERREZ ALBERTO</creatorcontrib><creatorcontrib>HEINER SOPHIE</creatorcontrib><title>Compositions and methods for treating liver disease</title><description>Compositions and methods for treating liver disease in a subject by increasing the transport or retention of transcription factor HNF4 [alpha] into the nucleus of liver cells in the subject are disclosed. In some embodiments, the methods comprise upregulating the expression or function of one or more transcription factors selected from the group consisting of PROX1, NR5A2, NR0B2, MTF1, SREBP1, EP300 and POM121C and functional fragments thereof, and/or down-regulating the expression or function of one or more transcription factors selected from the group consisting of DNAJB1/HSP40, ATF6, ATF4 and PERK and functional fragments thereof.
公开了通过增加转录因子HNF4α到受试者的肝细胞的核中的转运或保留来治疗受试者肝病的组合物和方法。在一些实施方式中，所述方法包括上调一种或多种选自由PROX1、NR5A2、NR0B2、MTF1、SREBP1、EP300和POM121C组成的组的转录因子及其功能性片段的表达或功能，和/或下调一种或多种选自DNAJB1/HSP40、ATF6、ATF4和PERK的转录因子及其功能性片段的表达或功能。</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDB2zs8tyC_OLMnMzytWSMxLUchNLcnITylWSMsvUigpSk0sycxLV8jJLEstUkjJLE5NLE7lYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxzn6GhqZGBpaWRsaOxsSoAQAelCyt</recordid><startdate>20221018</startdate><enddate>20221018</enddate><creator>OSTROWSKA ANNA</creator><creator>TAFARON, ERIC, N</creator><creator>FRAUENHOF NAVARRO NATALIA</creator><creator>FOX IAN</creator><creator>MICHALOPOULOS, GEORGE, K</creator><creator>TAKEISHI KAZUKI</creator><creator>BELL ANDREW</creator><creator>GUZMAN LEPE JAVIER</creator><creator>SOTO GUTIERREZ ALBERTO</creator><creator>HEINER SOPHIE</creator><scope>EVB</scope></search><sort><creationdate>20221018</creationdate><title>Compositions and methods for treating liver disease</title><author>OSTROWSKA ANNA ; TAFARON, ERIC, N ; FRAUENHOF NAVARRO NATALIA ; FOX IAN ; MICHALOPOULOS, GEORGE, K ; TAKEISHI KAZUKI ; BELL ANDREW ; GUZMAN LEPE JAVIER ; SOTO GUTIERREZ ALBERTO ; HEINER SOPHIE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN115209923A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2022</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>OSTROWSKA ANNA</creatorcontrib><creatorcontrib>TAFARON, ERIC, N</creatorcontrib><creatorcontrib>FRAUENHOF NAVARRO NATALIA</creatorcontrib><creatorcontrib>FOX IAN</creatorcontrib><creatorcontrib>MICHALOPOULOS, GEORGE, K</creatorcontrib><creatorcontrib>TAKEISHI KAZUKI</creatorcontrib><creatorcontrib>BELL ANDREW</creatorcontrib><creatorcontrib>GUZMAN LEPE JAVIER</creatorcontrib><creatorcontrib>SOTO GUTIERREZ ALBERTO</creatorcontrib><creatorcontrib>HEINER SOPHIE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>OSTROWSKA ANNA</au><au>TAFARON, ERIC, N</au><au>FRAUENHOF NAVARRO NATALIA</au><au>FOX IAN</au><au>MICHALOPOULOS, GEORGE, K</au><au>TAKEISHI KAZUKI</au><au>BELL ANDREW</au><au>GUZMAN LEPE JAVIER</au><au>SOTO GUTIERREZ ALBERTO</au><au>HEINER SOPHIE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Compositions and methods for treating liver disease</title><date>2022-10-18</date><risdate>2022</risdate><abstract>Compositions and methods for treating liver disease in a subject by increasing the transport or retention of transcription factor HNF4 [alpha] into the nucleus of liver cells in the subject are disclosed. In some embodiments, the methods comprise upregulating the expression or function of one or more transcription factors selected from the group consisting of PROX1, NR5A2, NR0B2, MTF1, SREBP1, EP300 and POM121C and functional fragments thereof, and/or down-regulating the expression or function of one or more transcription factors selected from the group consisting of DNAJB1/HSP40, ATF6, ATF4 and PERK and functional fragments thereof.
公开了通过增加转录因子HNF4α到受试者的肝细胞的核中的转运或保留来治疗受试者肝病的组合物和方法。在一些实施方式中，所述方法包括上调一种或多种选自由PROX1、NR5A2、NR0B2、MTF1、SREBP1、EP300和POM121C组成的组的转录因子及其功能性片段的表达或功能，和/或下调一种或多种选自DNAJB1/HSP40、ATF6、ATF4和PERK的转录因子及其功能性片段的表达或功能。</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN115209923A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | Compositions and methods for treating liver disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T00%3A49%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=OSTROWSKA%20ANNA&rft.date=2022-10-18&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN115209923A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |